Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial.
Dean A FollmannHolly E JanesOlive D BuhuleHonghong ZhouBethany M BironKristen MarksKaren L KotloffMichaël DesjardinsLawrence CoreyKathleen M NeuzilJacqueline M MillerHana M El SahlyLindsey R BadenPublished in: Annals of internal medicine (2022)
National Institute of Allergy and Infectious Diseases of the National Institutes of Health.
Keyphrases
- placebo controlled
- double blind
- infectious diseases
- clinical trial
- phase ii
- phase iii
- study protocol
- quality improvement
- coronavirus disease
- sars cov
- open label
- phase ii study
- healthcare
- public health
- respiratory syndrome coronavirus
- mental health
- randomized controlled trial
- squamous cell carcinoma
- climate change
- social media